A Novel 2-Metagene signature to identify high-risk HNSCC patients amongst those who are clinically at intermediate risk and are treated with PORT.

Published in Cancers, 2022

Recommended citation: Patil, S., et al. (2022). "A Novel 2-Metagene signature to identify high-risk HNSCC patients." Cancers, 14(12), 3031. https://www.mdpi.com/2072-6694/14/12/3031